What will happen to HIV and TB under COVID-19? Our editor-in-chief Mia Malan spoke to an excellent panel to answer this question.
Living with HIV and other diseases, cancer or opportunistic infections
News
May 13, 2020
With the rapid spread of COVID-19 across Africa, m2m President & CEO, Frank Beadle de Palomo, looks at how countries and organisations are harnessing lessons learned from the HIV/AIDS response to mitigate the impact of this new pandemic.
Resource
December 16, 2019
A study from Tanzania seeking to assess the prevalence and management of drug-drug interactions in a rural setting.
Resource
October 18, 2019
BACKGROUND: Gauteng Province has the second lowest tuberculosis (TB) incidence rate in South Africa but the greatest proportion of TB/HIV co-infectio
Resource
July 31, 2019
In 2017, tuberculosis caused an estimated 1·6 million deaths, including 300 000 deaths among people with HIV, and surpassed HIV/AIDS to become the leading infectious cause of mortality worldwide. Approximately 36% of tuberculosis cases each year (around 3·5 million cases) are not diagnosed or rep
Resource
April 12, 2019
HIV-positive men have a high burden of genital HPV infection and AGW. ART and HPV vaccine could reduce this burden.
Resource
April 12, 2019
PLHIV with persistent TB symptoms require further evaluation for TB using all available modalities, and for food insecurity in those with weight loss.
Resource
April 12, 2019
OBJECTIVES: HIV infection has been associated with an impaired lung function in high-income countries, but the association between HIV infection and pulmonary function in Sub-Saharan Africa remains unclear.
Resource
April 12, 2019
Despite successful treatment, retreatment TB survivors retain a substantial risk of morbidity and mortality.
Resource
April 12, 2019
Cardiovascular disease (CVD) risk among people living with HIV is elevated due to persistent inflammation, hypertension and diabetes comorbidity, lifestyle factors and exposure to antiretroviral therapy (ART). Data from Africa on how CVD risk affects morbidity and mortality among ART patients are lacking. We explored the effect of CVD risk factors and the Framingham Risk Score (FRS) on medium-term ART outcomes.
